Difference between revisions of "Nivolumab and relatlimab (Opdualag)"
Jump to navigation
Jump to search
m |
m |
||
| (3 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
==Mechanism of action== | ==Mechanism of action== | ||
From the NCI Drug Dictionary (for relatlimab): A monoclonal antibody directed against the inhibitor receptor lymphocyte activation gene-3 (LAG-3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, relatlimab binds to LAG-3 on tumor infiltrating lymphocytes (TILs). This may activate antigen-specific T lymphocytes and enhance cytotoxic T cell-mediated tumor cell lysis, which leads to a reduction in tumor growth. | From the NCI Drug Dictionary (for relatlimab): A monoclonal antibody directed against the inhibitor receptor lymphocyte activation gene-3 (LAG-3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, relatlimab binds to LAG-3 on tumor infiltrating lymphocytes (TILs). This may activate antigen-specific T lymphocytes and enhance cytotoxic T cell-mediated tumor cell lysis, which leads to a reduction in tumor growth. | ||
| + | |||
| + | ==Toxicity management== | ||
| + | *[[Immunotherapy toxicity management]] | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| Line 6: | Line 9: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | *2022-03-18: Approved for adult and pediatric patients 12 years of age or older with unresectable or metastatic [[melanoma]]. ''(Based on RELATIVITY-047)'' |
| − | + | ==History of changes in EMA indication== | |
| + | *2022-09-15: initial authorization for the first line treatment of advanced (unresectable or metastatic) [[melanoma]] in adults and adolescents 12 years of age and older with tumour cell PD L1 expression < 1%. | ||
==Also known as== | ==Also known as== | ||
*'''Code name:''' BMS-986016 | *'''Code name:''' BMS-986016 | ||
| Line 19: | Line 23: | ||
[[Category:Melanoma medications]] | [[Category:Melanoma medications]] | ||
[[Category:Combination drugs]] | [[Category:Combination drugs]] | ||
| + | [[Category:EMA approved in 2022]] | ||
[[Category:FDA approved in 2022]] | [[Category:FDA approved in 2022]] | ||
Latest revision as of 14:11, 7 May 2023
Mechanism of action
From the NCI Drug Dictionary (for relatlimab): A monoclonal antibody directed against the inhibitor receptor lymphocyte activation gene-3 (LAG-3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, relatlimab binds to LAG-3 on tumor infiltrating lymphocytes (TILs). This may activate antigen-specific T lymphocytes and enhance cytotoxic T cell-mediated tumor cell lysis, which leads to a reduction in tumor growth.
Toxicity management
Diseases for which it is used
History of changes in FDA indication
- 2022-03-18: Approved for adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma. (Based on RELATIVITY-047)
History of changes in EMA indication
- 2022-09-15: initial authorization for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell PD L1 expression < 1%.
Also known as
- Code name: BMS-986016
- Generic name: nivolumab and relatlimab-rmbw
- Brand name: Opdualag